In Silico Molecular Modelling: Key Technologies in the Drug Discovery Process to Combat Multidrug Resistance

2019 ◽  
pp. 213-238
Author(s):  
Garima Saxena ◽  
Mala Sharma ◽  
Faria Fatima ◽  
Preeti Bajpai ◽  
Salman Akhtar
Keyword(s):  
Multidrug Resistance ◽  
Drug Discovery ◽  
Molecular Modelling ◽  
In Silico ◽  
Discovery Process ◽  
Drug Discovery Process ◽  
Key Technologies

scholarly journals In Silico Drug Repositioning Against Human NRP1 to Block SARS-CoV-2 Host Entry

2020 ◽  
Author(s):  
Seref Gul
Keyword(s):  
Drug Discovery ◽  
In Silico ◽  
Structural Information ◽  
Drug Repositioning ◽  
Experimental Studies ◽  
Md Simulations ◽  
Drug Binding ◽  
Discovery Process ◽  
Drug Discovery Process ◽  
S Protein

Despite COVID-19 turned into a pandemic, no approved drug for the treatment or globally available vaccine is out yet. In such a global emergency, drug repurposing approach that bypasses a costly and long-time demanding drug discovery process is an effective way in search of finding drugs for the COVID-19 treatment. Recent studies showed that SARS-CoV-2 uses neuropilin-1 (NRP1) for host entry. Here I took advantage of structural information of the NRP1 in complex with C-terminal of spike (S) protein of SARS-CoV-2 to identify drugs that may inhibit NRP1 and S protein interaction. U.S. Food and Drug Administration (FDA) approved drugs were screened using docking simulations. Among top drugs, well-tolerated drugs were selected for further analysis. Molecular dynamics (MD) simulations of drugs-NRP1 complexes were run for 100 ns to assess the persistency of binding. MM/GBSA calculations from MD simulations showed that eltrombopag, glimepiride, sitagliptin, dutasteride, and ergotamine stably and strongly bind to NRP1. In silico Alanine scanning analysis revealed that Tyr<sup>297</sup>, Trp<sup>301</sup>, and Tyr<sup>353</sup> amino acids of NRP1 are critical for drug binding. Validating the effect of drugs analyzed in this paper by experimental studies and clinical trials will expedite the drug discovery process for COVID-19.

Bioinformatics and Chemoinformatics: Key Technologies in the Drug Discovery Process

2009 ◽  
pp. 45-57 ◽  
Author(s):  
Andreas Krasky ◽  
Andreas Rohwer ◽  
Richard J. Marhfer ◽  
Paul M. Selzer
Keyword(s):  
Drug Discovery ◽  
Discovery Process ◽  
Drug Discovery Process ◽  
Key Technologies

scholarly journals In-Silico Drug Design: A revolutionary approach to change the concept of current Drug Discovery Process

2013 ◽  
Vol 1 (02) ◽  
pp. 60-73 ◽  
Author(s):  
Lakhyajit Boruah ◽  
Aparoop Das ◽  
Lalit Mohan Nainwal ◽  
Neha Agarwal ◽  
Brajesh Shankar
Keyword(s):  
Drug Discovery ◽  
Drug Design ◽  
In Silico ◽  
Traditional Approach ◽  
Discovery Process ◽  
Drug Discovery Process ◽  
Chemical Library ◽  
In Silico Drug Design ◽  
Modern Drug ◽  
Small Molecule Libraries

Computational methods play a central role in modern drug discovery process. It includes the design and management of small molecule libraries, initial hit identification through virtual screening, optimization of the affinity as well as selectivity of hits and improving the physicochemical properties of the lead compounds. In this review article, computational drug designing approaches have been elucidated and discussed. The key considerations and guidelines for virtual chemical library design and whole drug discovery process. Traditional approach for discovery of a new drug is a costly and time consuming affair besides not being so productive. A number of potential reasons witness choosing the In-silico method of drug design to be a more wise and productive approach. There is a general perception that applied science has not kept pace with the advances of basic science. Therefore, there is a need for the use of alternative tools to get answers on efficacy and safety faster, with more certainty and at lower cost. In-silico drug design can play a significant role in all stages of drug development from the initial lead designing to final stage clinical development.

scholarly journals In-silico drug design: An approach which revolutionarised the drug discovery process

2013 ◽  
Vol 1 (1) ◽  
Author(s):  
A Wadood ◽  
N Ahmed ◽  
L Shah ◽  
A Ahmad ◽  
H Hassan ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Drug Design ◽  
In Silico ◽  
Discovery Process ◽  
Drug Discovery Process ◽  
In Silico Drug Design

In silico pharmacology for a multidisciplinary drug discovery process

2012 ◽  
Vol 27 (4) ◽  
Author(s):  
Santiago Schiaffino Ortega ◽  
Luisa Carlota López Cara ◽  
María Kimatrai Salvador
Keyword(s):  
Drug Discovery ◽  
In Silico ◽  
Discovery Process ◽  
Drug Discovery Process

scholarly journals Phytochemical Properties and Pharmcological Activities of Nicotiana Tabacum: A Review

2013 ◽  
Vol 1 (02) ◽  
pp. 74-82
Author(s):  
Aarti Rawat ◽  
Rakesh Roshan Mali
Keyword(s):  
Drug Discovery ◽  
Drug Design ◽  
In Silico ◽  
Traditional Approach ◽  
Discovery Process ◽  
Drug Discovery Process ◽  
Chemical Library ◽  
Modern Drug ◽  
Small Molecule Libraries ◽  
Hit Identification

Computational methods play a central role in modern drug discovery process. It includes the design and management of small molecule libraries, initial hit identification through virtual screening, optimization of the affinity as well as selectivity of hits and improving the physicochemical properties of the lead compounds. In this review article, computational drug designing approaches have been elucidated and discussed. The key considerations and guidelines for virtual chemical library design and whole drug discovery process. Traditional approach for discovery of a new drug is a costly and time consuming affair besides not being so productive. A number of potential reasons witness choosing the In-silico method of drug design to be a more wise and productive approach. There is a general perception that applied science has not kept pace with the advances of basic science. Therefore, there is a need for the use of alternative tools to get answers on efficacy and safety faster, with more certainty and at lower cost. In-silico drug design can play a significant role in all stages of drug development from the initial lead designing to final stage clinical development.

scholarly journals In Silico Drug Repositioning Against Human NRP1 to Block SARS-CoV-2 Host Entry

2020 ◽  
Author(s):  
Seref Gul
Keyword(s):  
Drug Discovery ◽  
In Silico ◽  
Structural Information ◽  
Drug Repositioning ◽  
Experimental Studies ◽  
Md Simulations ◽  
Drug Binding ◽  
Discovery Process ◽  
Drug Discovery Process ◽  
S Protein

Despite COVID-19 turned into a pandemic, no approved drug for the treatment or globally available vaccine is out yet. In such a global emergency, drug repurposing approach that bypasses a costly and long-time demanding drug discovery process is an effective way in search of finding drugs for the COVID-19 treatment. Recent studies showed that SARS-CoV-2 uses neuropilin-1 (NRP1) for host entry. Here I took advantage of structural information of the NRP1 in complex with C-terminal of spike (S) protein of SARS-CoV-2 to identify drugs that may inhibit NRP1 and S protein interaction. U.S. Food and Drug Administration (FDA) approved drugs were screened using docking simulations. Among top drugs, well-tolerated drugs were selected for further analysis. Molecular dynamics (MD) simulations of drugs-NRP1 complexes were run for 100 ns to assess the persistency of binding. MM/GBSA calculations from MD simulations showed that eltrombopag, glimepiride, sitagliptin, dutasteride, and ergotamine stably and strongly bind to NRP1. In silico Alanine scanning analysis revealed that Tyr<sup>297</sup>, Trp<sup>301</sup>, and Tyr<sup>353</sup> amino acids of NRP1 are critical for drug binding. Validating the effect of drugs analyzed in this paper by experimental studies and clinical trials will expedite the drug discovery process for COVID-19.

Sign in / Sign up

Export Citation Format

Share Document